Patient-Focused Drug Development Public Meeting and Scientific workshop on Female Sexual Dysfunction

FDA is conducting a Patient-Focused Drug Development public meeting and scientific workshop on Female Sexual Dysfunction (FSD) on October 27 and October 28.

Day 1 – October 27th Patient-Focused Drug Development Public Meeting
FDA is interested in obtaining patient input on:
1. The impact of the most common form of FSD, female sexual interest/arousal disorder (FSIAD) on daily life
2. Patients’ views on currently available therapies to treat the condition

Day 2 – October 28th Scientific Workshop
The scientific workshop will include discussion on scientific challenges related to:
1. Diagnosis of the condition for clinical trials and in clinical practice
2. Ensuring valid patient-reported outcome measures for the key efficacy endpoints used in clinical trials

This website will be updated as meeting materials are developed.

Date(s) and Time(s) 

October 27, 2014 (12:00 p.m. to 5:00 p.m.)
October 28, 2014 (8:00 a.m. to 5:00 p.m.)


FDA White Oak Campus
10903 New Hampshire Avenue
Building 31, Room 1503 B and C
Silver Spring, MD 20993
(Information about arrival to FDA's White Oak campus)


To register for this meeting, visit http://patient-focused-female-sexual-dysfunction.eventbrite.comdisclaimer icon.
Registration will close on October 20, 2014.


Page Last Updated: 08/11/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.